Category Archives: Regenerative Medicine

SIRIUS MANAGEMENT CONSULTING

The biopharmaceutical industry is rapidly growing with most pharma companies shifting their focus on increasing the efficacy and safety of biopharmaceutical drugs, thereby allowing them to command high prices for innovative drugs.

Chicago, July 25, 2022 (GLOBE NEWSWIRE) -- According to Ariztons latest research report, the global biopharmaceutical excipients market to grow at a CAGR of 7.56% from 2022 to 2027. The rising demand for biopharmaceuticals is the major factor driving the demand for excipients used in the manufacturing of various biologic drugs. The need for diverse biological treatments is rising as the burden of cancer increases. Both large and small biopharmaceutical businesses continue to look for the molecular causes of cancer and create medications to stop malignant cells. As a result, the biopharma sector is playing a key role in determining many facets of the oncology market.

Cell-based therapy is the fastest-growing segment of regenerative medicine, a field that promises to cure diseases that are not treated by other small molecules or biological drugs. Vaccines are commonly used biologics that are witnessing high demand, especially since the COVID-19 outbreak. Due to the increased production of vaccines, the demand for vaccine-based excipients has increased drastically. In addition, new cell & gene therapies for the treatment of various diseases are also growing. Thus, the need for excipients used in their formulation is likely to grow.

Biopharmaceuticals Excipients Market Report Scope

Report Attributes

Details

MARKET SIZE (2027)

$3.23 Billion

MARKET SIZE (2021)

$2.08 Billion

CAGR (2022-2027)

7.56%

BASE YEAR

2021

FORECAST YEAR

2022-2027

MARKET SEGMENTS

Excipient, Biologics, Scale of Operation

GEOGRAPHIC ANALYSIS

North America, APAC, Europe, Latin America, and MEA

KEY VENDORS

Merck KGAA, BASF SE, Avantor, Evonik Industries, and Roquette

Click Here to Download the Free Sample Report

Emerging Demand for Novel Excipients in Drug Product Development

Novel excipients are playing a crucial role in developing new, improved, and safe drugs for the biopharmaceutical market. Several companies prefer to bring sophisticated and innovative formulations that involve novel excipients. To modernize drug formulation and biopharmaceutical development processes, the FDA launches a testing program to check the safety and suitability of novel inactive ingredients in new drugs and biologics applications. The aim is to encourage sponsors of clinical trials to formulate innovative therapies with those new excipients that the FDA finds acceptable for use under this program.

Story continues

Moreover, excipient makers acknowledge that they will be more willing to invest in the production and the characterization of novel excipients if it is possible to gain the FDA review on the benefits of the product outside clinical testing for a new molecular entity. The initiative and ongoing efforts to set international standards for excipient use have the potential to enhance the drug formulation and support modern manufacturing and quality control efforts.

Increasing Need for Outsourcing Biopharmaceutical Excipient Manufacturing

Outsourcing is a common way for pharmaceutical companies to increase their operational efficiencies, expand their geographic footprints, and expand their therapeutic expertise and on-demand services. Outsourcing helps companies to save on resource costs, infrastructure costs, and other overheads. Cost savings remain the main reason for outsourcing multiple features across the industry, but some major pharmaceutical companies have radically changed their outsourcing motives. In the current market, pharmaceutical companies cite improved quality and faster time to market as the main reasons for outsourcing business functions to CROs and CDMOs.

Over the last decade, more and more pharmaceutical and biotechnology companies have turned to complementary metal-oxide semiconductor (CMOs) and contract development and manufacturing company (CDMOs) to help them perform, develop, and manufacture the latest innovations. Outsourcing is a multi-billion-dollar industry today. Most spending is focused on early development, and about two-thirds of annual spending is outsourced.

Key Highlights

In 2021, the monoclonal antibodies segment accounted for the largest share of 45% in the global biopharmaceutical excipients market

The commercial segment dominated the market by contribution largest share of over 73% in 2021.

In 2021, the pharma & biotech companies segment accounted for the larger share of 57.63% in the global biopharmaceutical excipients market.

Key Offerings:

Market Size & Forecast by Volume | 20212027

Market Size & Forecast by Value | 20212027

Market Dynamics Leading trends, growth drivers, restraints, and investment

OpportunitiesMarket Segmentation A detailed analysis by excipient, biologics, scale of operation, end-user, and geography

Competitive Landscape 6 key vendors and 27 other vendors

Market Segmentation

Excipient

Biologics

Monoclonal Antibodies

Vaccines

Others

Scale Of Operation

End-User

Geography

North America

Europe

Germany

France

UK

Switzerland

Italy

Spain

APAC

China

Japan

South Korea

India

Australia

Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

South Africa

Competitive Analysis

The global biopharmaceutical excipients market is fragmented, with revenue generated by vendors ranging from emerging mid-sized to established players. Major players are concentrating on strategic licensing, acquisitions, and collaboration agreements with growing players to enter the biopharmaceutical excipients market and to quickly access commercially launched products. Companies are also launching advanced and novel excipient solutions to support pharma drug development. They are focusing more on distribution chains and are providing the required demand for the biopharmaceutical excipients. Players are also focusing on market expansion in existing and newer markets to cater to the needs of an increasing customer base, widening their product portfolios, and boosting their production capabilities that can help in gaining traction from end-users.

Vendors

Merck KGAA

BASF SE

Avantor

Evonik Industries

Roquette Freres

Other Prominent Vendors

Aceto

Angus Chemical

Apothecon

Ashland Global

BioSpectra

BOC Sciences

C.G. Group

Clariant

Colorcon

DFE Pharma

DOW

Eastman Chemical

IMCD N.V.

Innophos

Invitria

JRS Pharma

Kirsch Pharma

Meggle

Novo Nordisk

Here is the original post:
Biopharmaceutical Excipients Market to Reach $3.2 Billion by 2027. Rising Demand for Vaccines and Cell & Gene Therapy-based Excipients are the...

July 12, 2022

Company Name:

HEALIOS K.K.

Representative:

Hardy TS Kagimoto, Chairman & CEO

(TSE Growth Code: 4593)

Healios eNK Cells: Regenerative Medicine Product Quality Consultation

with the PMDA for Planned Clinical Trials

HEALIOS K.K. ("Healios") is developing next-generation cancer immunotherapies for solid tumors using NK cells*1 derived from allogeneic iPSCs (Development Code: HLCN061 "eNK cells") whose specific functions have been enhanced with gene editing technology. In preparation for the start of clinical trials using eNK cells, we have conducted a regenerative medicine product quality consultation*2 (face-to-face advice) with the Pharmaceuticals and Medical Devices Agency (PMDA).

Healios has succeeded in developing eNK cells through its own research and has confirmed that eNK cells have anti-tumor effects in mice engrafted with human lung cancer cells and human liver cancer cells. We are conducting joint research with the National Cancer Center Japan, Hiroshima University, and the Hyogo Medical University, to evaluate the effect of eNK cells in various human solid cancers. Furthermore, we have established an automated, 3D perfusion bioreactor based manufacturing system that enables efficient and stable mass production of eNK cells for the manufacture of investigational product. Healios initiated the operations of its Cell Processing Center (CPC), a GMP manufacturing facility based on these technologies, and is advancing preparations for eNK clinical trials.

As part of these preparations, we have begun consultations with the PMDA through a formal regenerative medicine product quality consultation process. In an initial face-to-face consultation meeting, we have discussed with the authorities genome analysis and evaluation of transgenic iPS cells for the purpose of assessing the quality of HLCN061, among other matters. We will continue with consultations with the PMDA as we work towards the submission of an investigational new drug application and the start a clinical trial in FY2024.

Even though the advent of molecular targeted drugs and cancer immunotherapy has improved treatment outcomes for some cancer patients, the efficacy of existing treatments for solid tumors remains poor. Healios is committed to its continued research and development of effective treatments for solid cancer patients.

*1 Natural killer (NK) cells

Natural killer (NK) cells are a subset of lymphocytes, a type of white blood cell. NK cells play a central role in a cell mediated defense system that human bodies naturally have, and attack cancer cells and virus-infected cells. The expected efficacy of treatments using NK cells includes life- extension, promotion of healing, relief of symptoms, and improvement of quality of life.

1

*2 Regenerative medicine product quality consultation

Guidance and advice are provided as a specialized consultation on matters related to the quality of processed cells, etc. and regenerative medicine products, such as specifications, test methods, stability, and manufacturing methods.

About Pharmaceuticals and Medical Devices Agency (PMDA):

PMDA is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare. Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices. It conducts scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety. It is also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.

In response to applications from sponsors, etc., we provide guidance and advice on clinical trials for pharmaceuticals, medical devices, regenerative medicine products, etc., as well as on clinical trials for reevaluation and reassessment. https://www.pmda.go.jp/english/review-services/consultations/0002.html

About Healios' eNK cells:

Healios eNK cells are a gene edited iPSC-NK cell therapy with several functional enhancements achieved through gene-editing including enhanced cytotoxicity towards cancer, improved capability to migrate and infiltrate solid tumors, and the ability to recruit host immune cells. Healios has succeeded in developing eNK cells through its own research and has confirmed that eNK cells have anti-tumor effects in mice engrafted with human lung cancer cells and human liver cancer cells. In joint research with the National Cancer Center Japan("the NCCJ") we are evaluating the antitumor effects of eNK cells in a PDX mouse disease model created using the NCCJ's JPDX samples. Furthermore, Healios is conducting joint research on cancer immunotherapies using eNK cells for hepatocellular carcinoma with Hiroshima Universityand for mesothelioma with Hyogo Medical University. Healios is continuing with in vitro and animal testing of its eNK cell therapy in preparation for its first clinical trials.

About Healios:

Healios is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan, where it has established a proprietary, gene-edited "universal donor" induced pluripotent stem cell (iPSC) line to develop next generation regenerative treatments in immuno- oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios' lead iPSC-derived cell therapy candidate, HLCN061, is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene editing. Its near-term pipeline includes the somatic stem cell product HLCM051, which has been evaluated in Japan in Phase 2/3 and Phase 2 trials in ischemic stroke and acute respiratory distress syndrome (ARDS), respectively. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593). https://www.healios.co.jp/en

Contact:

Department of Corporate Communications, HEALIOS K.K.

E-mail: ir@healios.jp

2

Read more here:
Healios eNK Cells: Regenerative Medicine Product Quality Consultation with the PMDA for Planned Clinical Trials - Marketscreener.com

A Tokyo Medical and Dental University (TMDU) team announced on July 7 that it has conducted the worlds first clinical transplant of a mini organ into a patient with ulcerative colitis, an intractable disease. Part of a clinical study, the mini organ is made from cells obtained from the patient, and functions like a large intestine.

Researchers hope that the therapeutic method can possibly repair the ulcerated area of the intestine, which is difficult to treat with drugs. Its practical use as a new therapy in regenerative medicine is anticipated.

The surgery was conducted on an ulcerative colitis patient with refractory ulcers at the Tokyo Medical Dental University Hospital on July 5. Stem cells, which are tissue-building cells, were collected from the vicinity of a healthy colonic mucosa and cultured. Many spherical mini organs measuring at 0.1 ~ 1.2 millimeters were produced. These were then transplanted into the ulcerated area with an endoscope.

The surgery was successful and the patient was discharged from the hospital the following day. The team will monitor the patients condition over the next year to confirm safety and efficacy of the treatment.

At the press conference, Professor Ryuichi Okamoto stated, We were able to reach the starting line of a new medical therapy. We hope to continue a steady progression in our research and deliver the results to patients.

Mini organs are a collection of cells that bear the function and three-dimensional structure of actual organs. Also called organoids, their utilization in applied research in regenerative medicine is gaining momentum with various organs.

The surgery on July 5 is said to be the first ever full-scale organoid transplant to be conducted.

Ulcerative colitis is an intractable disease brought on for unknown reasons. It causes inflammation and ulcers along the mucosa of the colon, triggering symptoms such as abdominal pain and bloody diarrhea.

The number of patients is rapidly increasing, with an estimated 220,000 people affected in Japan. Symptoms can improve with anti-inflammatory drugs. However, if the disease becomes severe it could be difficult to repair or regenerate the ulcerated area using only symptomatic treatments available up to now.

Organoids bear a resemblance to the conditions of actual human tissues. Therefore, they are able to regenerate the ulcerated area because of their ability to attach to the affected area. Combined with the use of medication, a complete recovery is said to be possible.

(Read the report in Japanese at this link.)

Author: The Sankei Shimbun

Read the original here:
Tokyo Medical and Dental University Team Succeeds with First Mini Organ Transplant - JAPAN Forward

The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants

Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio's two cornea transplant products and has exclusive worldwide commercialization rights for these products

JENA, Germany and WINSTON SALEM, N.C., July 18, 2022 /PRNewswire/ -- Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.

Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio's two cornea transplant products and has exclusive worldwide commercialization rights for these products. Financial terms were not disclosed.

"This investment in Precise Bio is expected to complement our leading portfolio of cataract and corneal refractive workflow solutions," said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. "The technology has the potential to advance treatment options for corneal disease, as well as for elective procedures furthering enabling optimization of patient care."

"We are very excited with this partnership that builds on our successful, ongoing collaboration with ZEISS for the development of corneal tissues to address unmet needs in the field of ophthalmology," stated Aryeh Batt, Co- Founder and CEO of Precise Bio. "This strategic agreement leverages ZEISS' global leadership in ophthalmology and Precise' innovative and unique 4D bio-fabrication platform technology. We are confident that the synergy between the two companies will allow us to develop breakthrough solutions for recovering patients' eyesight, bringing hope to hundreds of millions of patients worldwide."

Precise Bio combines engineering, biomaterials, cell technology, bioengineering, and 3D printing into an unparalleled 4D bio-fabrication platform for transplantable organs and tissues. The Company's proprietary platform technology allows to fabricate tissues by 'printing' cells in a single-cell resolution and spatial accuracy, enabling complex organoid constructs with both structural integrity and long-term cell viability. Overcoming multiple technology challenges, Precise Bio's 4D bio-fabrication technology allows to reliably scale up tissue engineering for clinical use, and produce large quantities in a reproducible, quality controlled and cost-effective process. Precise Bio's ophthalmological pipeline consists of three products, the two cornea products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which demonstrated successful results in animal models. The Company's ophthalmological products address global markets exceeding $10 billion annually.

Bio-fabricated tissues comprised of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue in cases where there is lack of tissue or solve unmet therapeutic needs.

About ZEISSCarl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of 1,646.8m in fiscal year 2020/21 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit:www.zeiss.com/med

About Precise BioPrecise Bio develops regenerative medicine therapies that can transform patient care across a wide range of medical indications. Precise Bio's proprietary, break-through 4D bio-fabricating platform overcomes limitations of existing extrusion and ink-jet printers and paves the way for fabricating clinically viable tissues and organs. The Company's initial product pipeline is focused on ophthalmology and includes fabricated functional corneal grafts, intrastromal lenticules for treating keratoconus and vision correction,and a retinal implant for age-related macular degeneration. The Company also has earlier R&D programs to address unmet needs in additional medical indications, which are limited by the number of available donor tissues and organs, or where today's critical health problems can be solved using Precise Bio's naturally-based, hyper-accurate technology.

Precise Bio was founded in 2016 by Prof. Anthony Atala, MD, Director of the Wake Forest Institute of Regenerative Medicine (WFIRM), Prof. Shay Soker, PhD, from WFIRM and Mr. Aryeh Batt, who developed the Company's transformative laser printing technology. The Company operates out of two centers, in Winston Salem, NC and Modi'in, Israel.For more information, please visit http://www.precise-bio.com.

Photo - https://mma.prnewswire.com/media/1860898/Precise_Bio_Cornea.jpg

Precise Bio contact for investors:Eyal ArieliCFO/COOPrecise BioPhone: +972 76 539 1001[emailprotected]

Precise Biocontact for press / media:Tsipi HaitovskyGlobal Media LiaisonPrecise BioPhone: +972 52 598 9892[emailprotected]

ZEISS contact for investors:Sebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220-116[emailprotected]

ZEISS contact for the press / media:Laurie FergusonHead of Global Communications Ophthalmic DevicesCarl Zeiss MeditecPhone: +1 925 719 7825[emailprotected]

SOURCE Precise Bio

Read more:
Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology USA -...

Wilmington, Delaware, United States, July 18, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.: The market value of the global cell separation technologies market is estimated to be over US$ 20.3 Bn by 2031, according to a research report by Transparency Market Research (TMR). Hence, the market is expected expand at a CAGR of 11.9% during the forecast period, from 2022 to 2031.

According to the TMR insights on the cell separation technologies market, the prevalence of chronic disorders including obesity, diabetes, cardiac diseases, cancer, and arthritis is being increasing around the world. Some of the key reasons for this situation include the sedentary lifestyle of people, increase in the older population, and rise in cigarette smoking and alcohol consumption across many developed and developing nations. These factors are expected to help in the expansion of the cell separation technologies market during the forecast period.

Players in the global cell separation technologies market are increasing focus on the launch of next-gen products. Hence, they are seen increasing investments in R&Ds. Moreover, companies are focusing on different strategies including acquisitions and strengthening their distribution networks in order to stay ahead of the competition.

Request Brochure of Cell Separation Technologies Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

As per the Imperial College London, chronic diseases are expected to account for approximately 41 million deaths per year, which seven out of 10 demises worldwide. Of these deaths, approximately 17 million are considered to be premature. Hence, surge in cases of chronic diseases globally is resulting into increased need for cellular therapies in order to treat such disease conditions, which, in turn, is boosting the investments toward R&Ds, creating sales opportunities in the cell separation technologies market.

Cell Separation Technologies Market: Key Findings

Request for Analysis of COVID-19 Impact on Cell Separation Technologies Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

Cell Separation Technologies Market: Growth Boosters

Cell Separation Technologies Market: Regional Analysis

Get Exclusive PDF Sample Copy of Cell Separation Technologies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

Cell Separation Technologies Market: Key Players

Some of the key players profiled in the report are:

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1925

Cell Separation Technologies Market Segmentation

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Cell Culture Market: Rise in outsourcing activities and expansion of biopharmaceutical manufacturers are expected to drive the cell culture market during the forecast period

Cell Culture Media, Sera, and Reagents Market: The global cell culture media, sera, and reagents market is majorly driven by growth and expansion of biotechnology & pharmaceutical companies and academic & research institutes.

Stem Cells Market: The global stem cells market is majorly driven by rising applications of stem cells in regenerative medicines. Increase in the number of chronic diseases such as cardiac diseases, diabetes, cancer, etc.

Cell Line Authentication and Characterization Tests Market: Increase in the geriatric population and surge in incidence of chronic diseases are projected to drive the global cell line authentication and characterization tests market.

CAR T-cell Therapy Market: The CAR T-cell therapy market is expected to clock a CAGR of 30.6% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses.

Cell & Tissue Preservation Market: Rise in investments in the field of regenerative medicine research is estimated to propel the market. Human blood, tissues, cells, and organs own the capability to heal damaged tissues and organs with long-term advantages.

Placental Stem Cell Therapy Market: Placental stem cell therapy market is driven by prominence in treatment of age-related disorders/diseases and increase in awareness about stem cell therapies are projected to drive the global market in the near future.

Biotherapeutics Cell Line Development Market: The market growth will be largely driven by research and development activities due to which, new solutions and technologies have gradually entered the market.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Continue reading here:
Cell Separation Technologies Market Expands with Rise in Prevalence of Chronic Diseases, States TMR Study - GlobeNewswire

Treating Pain Origins with Minimally Invasive Techniques

CHALFONT, Pa., July 18, 2022 /PRNewswire/ -- Local Pain Medicine & Rehabilitation Practice, Pennsylvania Pain and Spine Institute (PA Pain and Spine) changes the way pain is treated with access to premier technologies and treatments unavailable elsewhere for patients in the region.

PA Pain and Spine is a professional medical center providing diagnostic and treatment services for various pain-related conditions in the Philadelphia region of Pennsylvania and beyond. With a team of highly qualified and trained providers, the Harvard-trained founders H. David Qu, MD and Robert Kelly, DO have led the practice to serve 800+ patients a week in both diagnosing and treating their chronic, pain-related conditions.

"Typically, when people hear the term 'Pain Management' they think of medication and a spiraling path of depression. When we started out and saw the available pain 'treatments' in the area, we realized there was a need for less medication and surgery and instead more true treatments. We wanted to be different. We wanted to learn everything we could to provide people in our community with the absolute best options available to treat any type of pain and related conditions at the source and allow them to get back to doing the things they love in life." states Founding Physician H. David Qu, MD.

The practice continues to grow to see more patients in need, beyond the Montgomery and Bucks counties in Pennsylvania, and offers access to various minimally invasive injection therapies, regenerative medicine therapies, medical acupuncture, cutting edge minimally invasive out-patient procedures and more all over the region.

With a strong focus on community support and helping people get their lives back, it comes as no surprise that the practice has hundreds of patient testimonials expressing how their lives have changed after working with this team.

"There is no limit for the future. We are constantly evolving and learning new treatment methodologies to better serve our community as the world changes. We want to be the team where people feel heard, and leave better than when they came in. The amount of dedication and passion our team has for helping others is limitless and we want to continue spreading this care across the state and beyond," states President and Founding Physician Robert Kelly, DO.

Patients and local community can learn more about the practice and the team of providers by visiting https://www.pennpain.com, or by calling the office at (215) 395-8888.

About PA Pain & Spine

Pennsylvania Pain and Spine Institute was founded in 2013 by Ivy League trained physicians Dr. David Qu, MD and Dr. Robert Kelly, DO. The practice is a pain management and rehabilitation privately-owned clinic with a focus on utilizing minimally invasive techniques and pain generator diagnostics in order to heal patients at the source. The practice currently has two offices located in Chalfont, Pennsylvania and Quakertown, Pennsylvania and treats patients with any type of pain.

Media Contact:Kelsey Voelker215.395.8888 x104[emailprotected]

SOURCE Pennsylvania Pain and Spine Institute

View post:
Local Pain Medicine Practice Changes the Way Pain is Treated - PR Newswire

Contributed Commentary by Per Hammer, Cytiva

July 15, 2022 | Historically, the heavily regulated biopharma industry has been slow to adopt new technologies. However, a shift toward automation is vital to ensure that next-generation solutionssuch as cell and gene therapiesare produced at scale.

Less than one in five senior pharma executives strongly believe that frontier technologies, such as artificial intelligence, are widely adopted to support automation and increase the speed of specific processes. With cell therapies approved by global regulatory bodies, it is time to accelerate smart technologies and cell and gene therapy manufacturing.

Todays cell therapy treatments are often made on a small-scale, include manual preparation steps, and are produced for a clinical trial setting. Researchers spend days processing cellular material, monitoring its growth during the expansion phase, and preparing for re-administration to the patient. This process is demonstrated in administering autologous treatments so that every patient receives a unique living drug.

Though the current process is complex, it offers inspiring outcomes. For example, on April 1, 2022, the Food and Drug Administration (FDA) approved Kite Pharmas Yescarta, a chimeric antigen receptor (CAR) T-cell therapy for adult patients with large B-cell lymphoma. This kind of cancer is usually resistant to initial treatment and relapses within one year. With FDA approval, Yescarta (axicabtagene ciloleucel) is now the second-line treatment, a first for an autologous CAR T-cell therapy.

Cell Therapy Enters Mainstream

The exceptional results emerging from cell therapy clinical trials suggest we are entering a new phase of medical treatmentone where we can expect far more from our healthcare interventions than we ever imagined. Following the regulatory approval of autologous CAR T-cell therapies, the global cancer treatment landscape is changing, and the future is bright.

The success of COVID-19 vaccines signaled the arrival of the genomic medicines ageone where we hope to see cell and gene therapies deliver long-term remission and even cures for patients with some of the most complex diseases. According to the Alliance for Regenerative Medicine 2021 Annual Report, nearly 60% of the ongoing regenerative medicine clinical trials studied prevalent diseases by the end of the calendar year. But to get these powerful treatments to those who need them, we must have an automated manufacturing infrastructure that can generate cell therapies to meet increased demand in the coming years.

Saving Time Through Automation

Time is of the utmost importance, as biopharma manufacturing involves patient cells that have limited viability. Manual approaches to cell therapy production are time-consuming, and tasks such as checking cells at regular intervals during expansion are laborious. Another time-draining factor is the workflow and cleaning routines involved in maintaining a safe lab environment.

Automated solutions reduce or remove many of these challenges. After setting up a process, an operator can focus on other things while critical parameters such as temperature, pH level, gas transfer, and flow rates are monitored and controlled without human intervention.

Reducing Risks for Better Results

Manual cell processing solutions are complex, with many checkpoints across isolation, expansion, harvesting, and preservation stages. Unfortunately, each of these steps increases the risk potential. Despite the research teams expertise, there is still a chance that materials could be inadvertently contaminated during numerous open stages.

Additionally, limited process control can lead to difficulties in achieving high reproducibility. An automated modular solution minimizes these risks by bringing multiple steps within a closed, highly regulated, and controlled system.

Improving Manufacturing Efficiency

Changing a manufacturing process requires multiple manual routines and adjustments that must be checked and documented. However, documentation and protocols are less helpful when a customized process is used because they only apply to that specific setup.

Standardization would effectively improve manufacturing efficiency. This approach would ensure that what is learned in one project can be referenced in future work, with data and documentation applicable across different technology applications. A modular chain of connected systems allows for process variation with instruments running in customized configurations. Additionally, having control of an individual instrument leads to the straightforward use of built-in software and sensors.

Automated Manufacturing: The Way Forward for Cell and Gene Therapy

By using automated manufacturing to minimize human interaction, time, and resource requirements, it is possible to increase production speed and lower some risks and costs associated with commercialization.

The industry is ever-changing and adjusting its complex, yet exciting challenges will take some time. However, automation can create a significant advantage over competitors, providing the tools needed to produce cell therapies with the highest levels of safety and efficacy for patients.

Per Hammer has two decades of experience in the biopharma industry, mainly supporting customers in academics through process development and manufacturing. Per joined Cytiva in 2001, taking on several distinct roles in the company. Most recently, he progressed from Product Manager Leader for the Bioprocess Automation and Digital Team to Senior Global Product Manager for the Cell & Gene Therapy Automation and Digital Solutions. He can be reached at per.hammer@cytiva.com.

See the article here:
Automating the Genomic Medicines of the Future - Bio-IT World

Wilmington, Delaware, United States, Transparency Market Research Inc.: Medical nonwoven disposables are highly essential products in the healthcare field. Increase in popularity of these products has been observed as they provide better hygiene condition and reduce the contamination. Nonwoven products have many advantages over woven products.

Read Report Overview - https://www.transparencymarketresearch.com/medical-nonwoven-disposables.html

Nonwoven products include surgical gowns, face masks, drapes, surgeon caps, bandages, and others. Medical nonwoven disposables are made up from materials such as polypropylene, polyethylene, polyamides & polyesters, and others.

Medical nonwoven disposables products consist of high-quality fabrics for complete safety and immunity of healthcare professionals

The global medical nonwoven disposables market is driven by technological advancements in healthcare, increase in demand for advancements in wound dressing techniques, and rise in government initiatives for manufacturing nonwoven medical fabric. Moreover, demand for polyethylene is high due to low cost.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2413

Increase in prevalence of hospital-acquired infections among the geriatric population is expected to propel the medical nonwoven disposables market. According to the U.S. Department of Health & Human Product estimates, the U.S. is expected to have about 72.1 million geriatric population by 2030, which is more than twice the number in 2000.

As per a research paper published in the Current Opinion in Microbiology in 2018, lower respiratory tract infections which also include pneumonia, are the sixth leading cause of deaths due to hospitalizations in the U.S. and more than 90% of deaths occur in individuals who are 65 years old or more

Nonwoven medical disposables provide increased levels of protection against infectious diseases. In the past few years, nonwoven materials have shown significant reduction in post-operative infection rate compared to woven materials.

The risk of developing infection is nearly 2.5 times higher with woven products than nonwovens. Such factors help drive the medical nonwoven disposables market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2413

Market Segmentation: Medical Nonwoven Disposables Market

Based on product, the global medical nonwoven disposables market has been divided into surgical products (drapes, gowns, caps, masks, and others), wound dressings (bandages, tapes, post-operative wound dressings, operative wound dressings, and dressing pads), and incontinence products (under pads and diapers)

In terms of material, the global medical nonwoven disposables market has been classified into polypropylene, polyethylene, acetate, rayon, polyamides & polyesters, acrylic, and others

In terms of end user, the global medical nonwoven disposables market has been categorized into hospitals, nursing homes, consumer & home healthcare, clinics, and ambulatory surgical centers

Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments from 2018 to 2028, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2028 along with market size estimations.

Get COVID-19 Analysis on Medical Nonwoven Disposables Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2413

Regional Overview: Medical Nonwoven Disposables Market

In terms of region, the global medical nonwoven disposables market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and future market value in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2018 to 2028, with their CAGRs from 2020 to 2028.

The study also offers a list of recommendations, highlights, and useful insights of the market which would help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=2413

Major Players

The report concludes with the company profiles section that includes key information about the major players in the market

Leading players analyzed in the medical nonwoven disposables market include

Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

More Trending Reports by Transparency Market Research

Unicompartmental Knee Prosthesis Market: https://www.transparencymarketresearch.com/unicompartmental-knee-prostheses-market.html

Polymerase Chain Reaction Market: https://www.transparencymarketresearch.com/pcr-technologies.html

Prefilled Syringes Market: https://www.transparencymarketresearch.com/prefilled-syringes-market.html

Hyaluronic Acid Products Market: https://www.transparencymarketresearch.com/hyaluronic-acid-products-market.html

Recto-vaginal Fistula Treatment Market: https://www.transparencymarketresearch.com/recto-vaginal-fistula-treatment-market.html

Urinary Catheters Market: https://www.transparencymarketresearch.com/urinary-catheters-market.html

Regenerative Medicine Market: https://www.transparencymarketresearch.com/regenerative-medicines-market.html

Wound Dressings Market: https://www.transparencymarketresearch.com/wound-dressing-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

The rest is here:
Medical Nonwoven Disposables Market: Increase in Demand for Advancements in Wound Dressing Techniques to Drive the Market - BioSpace

DUBLIN, July 15, 2022 /PRNewswire/ --The "Veterinary Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global veterinary medicine market reached a value of US$ 31.06 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 48.58 Billion by 2027, exhibiting a CAGR of 7.74% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Veterinary medicine is a branch of science that deals in the prevention, control, diagnosis, and treatment of diseases that affect the health of domestic and wild animals. It helps maintain the health of food-producing animals, inhibit the transmission of zoonotic diseases from animal species to humans, and ensure a safe supply of food worldwide. At present, the escalating consumption of animal-derived products is increasing the adoption of veterinary medicines to monitor the health of agricultural animals and prevent human exposure to diseases.

The growing trend of nuclear families and inflating income levels have increased the overall spending of individuals on pets globally. This, in confluence with the rising concerns among pet parents about the well-being of their pets, represents one of the major factors supporting the demand for veterinary medicines.

The increasing penetration of pet insurance is further influencing the market growth. Apart from this, the expanding animal husbandry activities, along with the escalating cases of zoonotic and chronic diseases among animals, are increasing the concerns about food safety. This, along with the increasing number of commercial animal-production programs, is promoting the adoption of veterinary medicines for better diagnosis and treatment for livestock.

Moreover, the easy availability of advanced diagnostic imaging, novel therapies, nuclear and regenerative medicines, laser diagnostics, and specialized surgeries in numerous vet hospitals and clinics is bolstering the market growth. Furthermore, biomedical researchers are developing safe and effective vaccines to prevent pet diseases, which is anticipated to strengthen the market growth.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Archer-Daniels-Midland Company, Boehringer Ingelheim GmbH, Cargill Incorporated, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Evonik Industries AG, Merck & Co. Inc., Neogen Corporation, Vetoquinol S.A., Virbac and Zoetis Inc.

Key Questions Answered in This Report:

How has the global veterinary medicine market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global veterinary medicine market?

What are the key regional markets?

What is the breakup of the market based on the product?

What is the breakup of the market based on the animal type?

What is the breakup of the market based on the route of administration?

What is the breakup of the market based on the distribution channel?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global veterinary medicine market and who are the key players?

What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Veterinary Medicine Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast

6 Market Breakup by Product6.1 Drugs6.1.1 Market Trends6.1.2 Key Segments6.1.2.1 Anti-infective6.1.2.2 Anti-inflammatory6.1.2.3 Parasiticide6.1.3 Market Forecast6.2 Vaccines6.2.1 Market Trends6.2.2 Key Segments6.2.2.1 Inactivated Vaccines6.2.2.2 Attenuated Vaccines6.2.2.3 Recombinant Vaccines6.2.3 Market Forecast6.3 Medicated Feed Additives6.3.1 Market Trends6.3.2 Key Segments6.3.2.1 Amino Acids6.3.2.2 Antibiotics6.3.3 Market Forecast

7 Market Breakup by Animal Type7.1 Production7.1.1 Market Trends7.1.2 Market Forecast7.2 Companion7.2.1 Market Trends7.2.2 Market Forecast

8 Market Breakup by Route of Administration8.1 Oral8.1.1 Market Trends8.1.2 Market Forecast8.2 Parenteral8.2.1 Market Trends8.2.2 Market Forecast8.3 Topical8.3.1 Market Trends8.3.2 Market Forecast

9 Market Breakup by Distribution Channel9.1 Veterinary Hospitals and Clinics9.1.1 Market Trends9.1.2 Market Forecast9.2 Point-of-Care Testing/In-house Testing9.2.1 Market Trends9.2.2 Market Forecast9.3 Others9.3.1 Market Trends9.3.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape15.1 Market Structure15.2 Key Players15.3 Profiles of Key Players15.3.1 Archer-Daniels-Midland Company15.3.1.1 Company Overview15.3.1.2 Product Portfolio15.3.1.3 Financials15.3.1.4 SWOT Analysis15.3.2 Boehringer Ingelheim GmbH15.3.2.1 Company Overview15.3.2.2 Product Portfolio15.3.3 Cargill Incorporated15.3.3.1 Company Overview15.3.3.2 Product Portfolio15.3.3.3 SWOT Analysis15.3.4 Ceva Sante Animale15.3.4.1 Company Overview15.3.4.2 Product Portfolio15.3.5 Dechra Pharmaceuticals PLC15.3.5.1 Company Overview15.3.5.2 Product Portfolio15.3.5.3 Financials15.3.6 Elanco Animal Health Incorporated15.3.6.1 Company Overview15.3.6.2 Product Portfolio15.3.6.3 Financials15.3.7 Evonik Industries AG15.3.7.1 Company Overview15.3.7.2 Product Portfolio15.3.7.3 Financials15.3.8 Merck & Co. Inc. 15.3.8.1 Company Overview15.3.8.2 Product Portfolio15.3.8.3 Financials15.3.9 Neogen Corporation15.3.9.1 Company Overview15.3.9.2 Product Portfolio15.3.9.3 Financials15.3.9.4 SWOT Analysis15.3.10 Vetoquinol S.A.15.3.10.1 Company Overview15.3.10.2 Product Portfolio15.3.10.3 Financials15.3.11 Virbac15.3.11.1 Company Overview15.3.11.2 Product Portfolio15.3.11.3 Financials15.3.11.4 SWOT Analysis15.3.12 Zoetis Inc.15.3.12.1 Company Overview15.3.12.2 Product Portfolio15.3.12.3 Financials15.3.12.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/kpoq5l

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/insights-on-the-veterinary-medicine-global-market-to-2027---by-product-animal-type-route-of-administration-distribution-channel-and-region-301587584.html

SOURCE Research and Markets

Go here to read the rest:
Insights on the Veterinary Medicine Global Market to 2027 - by Product, Animal Type, Route of Administration, Distribution Channel and Region - Yahoo...

Competitors in the Market, 3M, Novartis AG, Aspect Biosystems, Kite Pharma, Misonix, Takeda Pharmaceutical Company Limited, Tego Science, Vericel Corporation, Smith & Nephew plc, Androgen Co., Ltd, Bluebird bio, Other Prominent Players

The global regenerative medicine market size was 18.1 billion in 2021. The global regenerative medicine market is forecast to grow to US$ 128.1 billion by 2030 by registering a compound annual growth rate (CAGR) of 21.1% during the forecast period from 2022 to 2030.

Request To Download Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=Pol1134

The goal of the biomedical discipline of regenerative medicine is to repair damaged tissues and organs by renewing their structure and functionality. It involves the safe transplantation of stem cells made in the laboratory into the body to repair damaged bones, cartilage, blood vessels, and organs. Clinical therapeutic modalities include cell, immunomodulation, and tissue engineering frequently employ cellular and acellular regeneration drugs. They have the ability to treat a number of chronic conditions, including osteoporosis, Parkinsons disease, Alzheimers disease, and spinal cord injuries.

Factors Influencing the MarketThe growing geriatric population and rising cases of osteoporosis, Parkinsons disease, Alzheimers disease, and spinal cord injuries will fuel the demand for regenerative medicine during the study period. Apart from that, genetic disorders and cancer cases are also growing steeply, which will be opportunistic for the regenerative medicine market.

The rising healthcare sector all across the globe and favourable investments by government bodies will benefit the regenerative medicine market during the forecast period. Apart from that, rising investments in Research and Development aimed at enhancing the potential of regenerative medicine will also contribute to the growth of the regenerative medicine market during the forecast period. On the flip side, the high cost associated with regenerative medicine may act as a major restraint in the market growth during the forecast period.

COVID-19 Impact AnalysisThe demand for regenerative medicine is forecast to witness potential growth due to the COVID-19 pandemic. The pandemic highlighted the need to work on healthcare infrastructure. As a result of this, governments and private bodies started investing highly in the sector. Thus, it has been opportunistic for the regenerative medicine market during the forecast period.

Get a Sample PDF copy of the report :-https://reportocean.com/industry-verticals/sample-request?report_id=Pol1134

Regional AnalysisNorth America is expected to hold the highest share in the regenerative medicine market during the study period. The projected growth of this regional market will be due to the factors like high healthcare expenditure and increasing focus on stem cell banking, tissue engineering, and drug discovery in the region. Furthermore, the growing prevalence of disease and rising demand for stem cell therapy and cell immunotherapies will drive the growth of the regenerative medicine market. In addition, growing investments in the sector, combined with the early adoption of advanced technologies, will benefit this regional market during the study period.

Market SegmentationThe global regenerative medicine market segmentation focuses on Product, Application, End-User, and Region.By Product Type? Stem cell therapy? Biomaterial? Tissue Engineering? OthersBy Application? Bone Graft substitutes? Osteoarticular Diseases? Dermatology? Cardiovascular? Central Nervous System? OthersBy End-User? Hospitals? Special Clinics? Others

Download Sample Report, SPECIAL OFFER (Avail an Up-to 30% discount on this report):-https://reportocean.com/industry-verticals/sample-request?report_id=Pol1134

By Region? North Americao The U.S.o Canadao Mexico? EuropeWestern Europeo The UKo Germanyo Franceo Italyo Spaino Rest of Western EuropeEastern Europeo Polando Russiao Rest of Eastern Europe? Asia Pacifico Chinao Indiao Japano Australia & New Zealando ASEANo Rest of Asia Pacific? Middle East & Africa (MEA)o UAEo Saudi Arabiao South Africao Rest of MEA? South Americao Brazilo Argentinao Rest of South America

What are the key findings of the report?

This report provides comprehensive information on factors expected to influence the market growth and market share in the future.

The report offers the current state of the market and future prospects for various geographical regions.

This report provides both qualitative and quantitative information about the competitive landscape of the market.

Access full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=Pol1134

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com/

Follow this link:
Regenerative Medicine Market Latest, Segments Analysis and Opportunities 2022-2030 - Taiwan News